PHYXIOM LIMITED

Phyxiom Limited is an Irish health‑tech spin‑out of the Royal College of Surgeons in Ireland, founded by clinicians to improve the diagnosis and treatment of chronic respiratory disease. Drawing on more than a decade of research and a suite of patented algorithms, the company delivers a data‑driven platform that integrates smart inhalers, spirometry devices and patient‑generated data to provide clinicians with personalised, real‑time insights into asthma and COPD management.

The Phyxiom solution combines clinical oversight, advanced analytics and a diagnostics platform into an intelligent decision‑support system that fits seamlessly into existing hospital or primary‑care workflows. Patients benefit from a precise diagnosis, individualised treatment plans and a marked reduction in steroid use, while clinicians enjoy more efficient appointments, evidence‑based treatment decisions and a standardised view of each case. Health services see fewer unnecessary tests, shorter outpatient waiting lists and reduced emergency‑department demand thanks to better disease control.

Through multiple randomised‑control trials, Phyxiom has demonstrated up to a 30 % improvement in asthma control, a 20 % cut in steroid burden and a 60 % reduction in step‑up therapy, positioning the company as a leading innovator in respiratory healthcare for the 540 million patients worldwide living with asthma or COPD.